Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1

Inclusion Criteria: * Documented diagnosis of Primary Hyperoxaluria Type 1 Exclusion Criteria: * Clinically significant health concerns (with the exception of PH1) * Received an investigational agent within 30 days before the first dose of lumasiran or are in follow-up of another clinical study * Previously or currently participating in lumasiran clinical study * History of liver transplant